Ryo Takada, Miki Fujiwara, Masatoshi Maki, Naoyuki Nomura, Shintaro Kono, Akira Fujita, . . . Koji Tamura. (2024). Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: A case report. BMC.
Chicago Style (17th ed.) CitationRyo Takada, et al. Stage IV Renal Cell Carcinoma Achieves Pathologic Complete Response After Two Ipilimumab Plus Nivolumab Courses Despite Severe Immune-related Adverse Events: A Case Report. BMC, 2024.
MLA (9th ed.) CitationRyo Takada, et al. Stage IV Renal Cell Carcinoma Achieves Pathologic Complete Response After Two Ipilimumab Plus Nivolumab Courses Despite Severe Immune-related Adverse Events: A Case Report. BMC, 2024.
Warning: These citations may not always be 100% accurate.